Separately, Zacks Investment Research lowered Kamada from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 24th.
Shares of KMDA stock opened at $4.65 on Monday. Kamada has a 12-month low of $4.41 and a 12-month high of $6.96. The firm has a market capitalization of $207.02 million, a price-to-earnings ratio of -31.00 and a beta of 1.00. The business has a 50 day simple moving average of $5.15 and a 200 day simple moving average of $5.81. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.75 and a quick ratio of 1.22.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Kamada by 7.7% in the third quarter. Geode Capital Management LLC now owns 25,878 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 1,856 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Kamada by 9.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 52,003 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 4,350 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Kamada in the first quarter valued at $27,000. Wells Fargo & Company MN lifted its holdings in shares of Kamada by 1.5% in the fourth quarter. Wells Fargo & Company MN now owns 454,137 shares of the biotechnology company’s stock valued at $2,988,000 after purchasing an additional 6,829 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Kamada by 24.3% in the third quarter. Goldman Sachs Group Inc. now owns 49,564 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 9,701 shares in the last quarter.
About Kamada (Get Rating)
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.
- Get a free copy of the StockNews.com research report on Kamada (KMDA)
- MarketBeat: Week in Review 5/30 – 6/3
- Dividend Capture Strategy: What You Need to Know
- Xiaomi Co: Facing Macro Headwinds
- Don’t Bet On A Bounce For RH
- Okta On Verge Of Multi-Week Rally
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.